Trevi Therapeutics, Inc.: stockholders equity
Stockholders equity for Trevi Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Trevi Therapeutics, Inc. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 183,244,000 | USD | 2026-03-17 | 10-K · 0001193125-26-110783 |
| At date | 2024-12-31 | 99,644,000 | USD | 2026-03-17 | 10-K · 0001193125-26-110783 |
| At date | 2023-12-31 | 82,547,000 | USD | 2026-03-17 | 10-K · 0001193125-26-110783 |
| At date | 2022-12-31 | 107,459,000 | USD | 2025-03-18 | 10-K · 0000950170-25-041194 |
| At date | 2021-12-31 | 17,075,000 | USD | 2024-03-20 | 10-K · 0000950170-24-034167 |
| At date | 2020-12-31 | 27,282,000 | USD | 2023-03-16 | 10-K · 0000950170-23-008472 |
| At date | 2019-12-31 | 54,545,000 | USD | 2022-03-17 | 10-K · 0001564590-22-010875 |
| At date | 2018-12-31 | -109,494,000 | USD | 2021-03-25 | 10-K · 0001564590-21-015506 |
| At date | 2017-12-31 | -84,428,000 | USD | 2020-03-16 | 10-K · 0001564590-20-010996 |
Related financial histories
- Trevi Therapeutics, Inc.: total assets
- Trevi Therapeutics, Inc.: total liabilities
- Trevi Therapeutics, Inc.: cash and cash equivalents
- Trevi Therapeutics, Inc.: net income or loss
- Trevi Therapeutics, Inc.: operating cash flow
- Trevi Therapeutics, Inc.: capital expenditure payments
- Trevi Therapeutics, Inc.: financing cash flow
- Trevi Therapeutics, Inc.: investing cash flow
- Trevi Therapeutics, Inc.: retained earnings or deficit
- Trevi Therapeutics, Inc.: basic weighted-average shares
- Trevi Therapeutics, Inc.: diluted weighted-average shares
- Trevi Therapeutics, Inc.: basic earnings per share
- Trevi Therapeutics, Inc.: diluted earnings per share
- Trevi Therapeutics, Inc.: income tax expense or benefit
- Trevi Therapeutics, Inc.: net property, plant and equipment
- Trevi Therapeutics, Inc.: share-based compensation expense
- Trevi Therapeutics, Inc.: operating income or loss
- Trevi Therapeutics, Inc.: current assets
- Trevi Therapeutics, Inc.: interest expense
- Trevi Therapeutics, Inc.: current liabilities
- Trevi Therapeutics, Inc.: current accounts payable
- Trevi Therapeutics, Inc.: operating expenses
- Trevi Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Trevi Therapeutics, Inc. / CIK 0001563880
- Captured
- 2026-09-20T09:20:18.657Z
- SEC response SHA-256
c77ee339b1ec2eee829ed5933743e8b340cee184f1a69e432d33c9af83ae2098
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001563880.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))